Page last updated: 2024-10-15

trifazid

Cross-References

ID SourceID
PubMed CID135483901
SCHEMBL ID4931913
MeSH IDM0299159

Synonyms (11)

Synonym
isoniazid & rifampin & pyrazinamide
inh-rif-pza
[pentahydroxy-methoxy-heptamethyl-[(e)-(4-methylpiperazin-1-yl)iminomethyl]-dioxo-[?]yl] acetate; pyrazine-2-carboxamide; pyridine-4-carbohydrazide
rifampin & isoniazid & pyrazinamide
trifazid
isoniazid, rifampicin and pyrazinamide
rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-, mixt. with pyrazinecarboxamide and 4-pyridinecarboxylic acid hydrazide
myrene p
3-(((4-methyl-1-piperazinyl)imino)methyl)rifamycin mixt. with pyrazinecarboxamide and 4-pyridinecarboxylic acid hydrazide
isoniazid, pyrazinamide, rifampin drug combination
SCHEMBL4931913

Toxicity

ExcerptReference
" Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported."( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013
)

Pharmacokinetics

ExcerptReference
"This was a Phase II open-label multiple dose pharmacokinetic and safety study."( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013
)
"A total of 25 patients (56% male) completed the study; 21 had evaluable pharmacokinetic profiles."( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013
)
"Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV."( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013
)

Compound-Compound Interactions

ExcerptReference
" For TB drugs, equivalence was suggested for peak plasma concentrations when administered with and without efavirenz/tenofovir/emtricitabine."( Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013
)
" Three studies were conducted to evaluate the potential drug-drug interactions between delamanid and antiretroviral drugs, including ritonavir, a strong inhibitor of CYP3A4, and selected anti-TB drugs, including rifampin, a strong inducer of cytochrome P450 (CYP) isozymes."( Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C, 2016
)

Bioavailability

ExcerptReference
"The bioavailability of isoniazid, rifampin, and pyrazinamide in 2 combined formulations of the 3 drugs (Rifater) for use primarily in the short-course chemotherapy of tuberculosis has been studied in Chinese patients in Singapore and Hong Kong."( The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
Allen, BW; Chan, SL; Ellard, DR; Ellard, GA; Girling, DJ; Ng, HK; Nunn, AJ; Tan, TH; Teo, SK, 1986
)
"To examine the relative bioavailability of rifampicin, isoniazid and pyrazinamide after oral administration of the drugs given alone in comparison to that of the same drugs after administration of Trifazid."( Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Augustynowicz-Kopec, E; Grubek-Jaworska, H; Niemirowska-Mikulska, H; Safianowska, A; Stambrowska, H; Walkiewicz, R; Zwolska, Z, 1998
)
"The present study assesses bioavailability indices for rifampicin, isoniazid and pyrazinamide when administered to healthy volunteers separately or in a fixed triple-drug formulation, Rifater 125 SCT."( Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Chandrasekaran, V; Gurumurthy, P; Kumar, AK; Kumaraswami, V; Prabhakar, R; Ramachandran, G; Venkatesan, P; Vijayalakshmi, S; Vjayasekaran, V, 1999
)
"To compare the pharmacokinetics of rifampicin, isoniazid and pyrazinamide based on their blood concentrations up to 12 hours with the proportions of the doses of the drugs and their metabolites excreted in urine up to 12 hours, and to assess the bioavailability indices for the free and fixed triple drug formulations."( Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Chandrasekaran, V; Gurumurthy, P; Kumar, AK; Kumaraswami, V; Prabhakar, R; Ramachandran, G; Venkatesan, P; Vijayalakshmi, S; Vjayasekaran, V, 1999
)
"Human bioavailability studies provide direct straightforward information, particularly when studying compounds such as rifampicin and other major anti-tuberculosis drugs."( Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Chandrasekaran, V; Gurumurthy, P; Kumar, AK; Kumaraswami, V; Prabhakar, R; Ramachandran, G; Venkatesan, P; Vijayalakshmi, S; Vjayasekaran, V, 1999
)

Dosage Studied

ExcerptReference
"5% of tuberculosis (TB) cases reported in 2003 in Taipei City had no recorded pre-treatment body weight and that among those who had, inconsistent dosing of anti-TB drugs was frequent."( Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012
)
" The proportion of patients treated with consistent dosing of a 3-drug fixed-dose combination (FDC) increased from 73."( Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012
)
" Coadministration of Kaletra (lopinavir/ritonavir) with delamanid resulted in an approximately 25% higher delamanid area under the concentration-time curve from time 0 to the end of the dosing interval (AUCĪ„)."( Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C, 2016
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.92)18.7374
1990's20 (39.22)18.2507
2000's8 (15.69)29.6817
2010's21 (41.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (26.92%)5.53%
Reviews2 (3.85%)6.00%
Case Studies20 (38.46%)4.05%
Observational0 (0.00%)0.25%
Other16 (30.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]